

**Contact**

Marc Le Bozec, CEO

mlebozec@cytoo.com, +33 (0)6 82 26 17 29

Press release

For immediate release

24th, May 2013

Marc Le Bozec joins CYTOO as Chief Executive Officer

Grenoble, France, 24th May 2013 – CYTOO, a French biotechnology company providing research and development tools based on cell architecture, welcomes Marc Le Bozec as Chief Executive Officer.

For more than 15 years, Marc Le Bozec has been a major stakeholder in industrial and academic biotechnologies in France. For several years, he worked as a consultant in organization (Bossard Consultants) and in strategy (Arthur D. Little). He founded BioProtein Technologies and managed it for 8 years. He then joined Alfact Innovation as Chief Operating Officer, and contributed to the launch of a clinical trial for liver diseases. He then joined Collectis, and made it grow from a promising start-up to a European leader in many fields. He was Chief Financial Officer and Chief Executive Officer of the Collectis bioresearch subsidiary. Concurrently, Marc Le Bozec serves the community and is notably member of the Scientific Advisory Board at the Inserm in France (National Institute of Health and Medical Research) since 2008, and is currently part of initiatives such as ATIP-Avenir. Marc Le Bozec graduated from HEC School of Management.

Jacques Lewiner, President of the Supervisory Board, declares: “We are delighted with Marc’s arrival. He will help us turn CYTOO into a world leader in the sector”.

“I have been knowing and appreciating the team for several years, and I did not hesitate for a second when the opportunity to join CYTOO was offered to me. The company commercializes some of the world’s most innovative products in life science research and development” declares Marc Le Bozec. “We will consolidate the structure built by the founders to turn it into a European and a world leader.”

“The company keeps reinforcing its management to increase its growth. Marc Le Bozec’s arrival is another major advantage for a company whose technological expertise is already established”, adds Franck Lescure, member of the Supervisory Board and representative of AURIGA Partners, the company’s main stockholder.

[See Marc Le Bozec’s LinkedIn profile](#)

**Contact**

Marc Le Bozec, CEO

mlebozec@cytoo.com, +33 (0)6 82 26 17 29

Press release

About CYTOO

CYTOO is a distinctive life sciences systems & tools company offering disruptive solutions for cell-based assays and High Content Screening (HCS) that reinforce robustness, sensitivity and powerful quantification. The Company's 2D+ Cell Culture Platform and Custom Solutions are based on adhesive micropatterns, offering control over the cells' microenvironment, leading to normalized cell morphology and behavior. The technology allows the optimization or resurrection of complex or difficult cell-based assays and enables innovative assay development.

For more information about the complete product portfolio, visit www.cytoo.com

Additional Contacts

CYTOO SA

cloiraud@cytoo.com

Follow us